Status:
WITHDRAWN
Alemtuzumab and Rituximab in Aplastic Anemia
Lead Sponsor:
Hospital Universitario Dr. Jose E. Gonzalez
Conditions:
Aplastic Anemia
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.
Eligibility Criteria
Inclusion
- Patients with aplastic anemia diagnosis
Exclusion
- Patients with prior treatment with monoclonal antibodies and/or antithymocyte globulin.
- Patients with a diagnosis or history of HIV/AIDS, Hepatitis B, Hepatitis C, Cytomegalovirus.
- Patients who do not agree to sign a Letter of Informed Consent.
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01408342
Start Date
July 1 2011
End Date
January 1 2014
Last Update
January 7 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario, Dr. Jose E. Gonzalez
Monterrey, Nuevo León, Mexico, 64460